Previous 10 | Next 10 |
Healthcare development progress forecasts This article rewards investors who choose to direct their investments of TIME and capital to those securities with the highest likelihood of successful rates of return among alternatives compared under identical important measures. Readers famili...
SAN DIEGO , Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development for the...
Arena Pharmaceuticals, Inc. (ARNA) Wells Fargo Global Healthcare Conference September 4, 2019 8:30 AM ET Company Participants Kevin Lind – Chief Financial Officer Conference Call Participants Nick Abbott – Wells Fargo Securities LLC Presentation Nick Abbott...
In the Fall of 2018, United Therapeutics ( UTHR ) and MannKind ( MNKD ) announced a deal for a "secret molecule" for PAH which would have MannKind doing some concept formulation work. Upon completion of that formulation work, United Therapeutics would make a decision on whether or not to move ...
Several years ago, Al Mann founded MannKind ( MNKD ) with a vision. Part of that vision was Afrezza. Early investors eagerly supported the concept of his vision. It was easy to buy into. Inhaled insulin vs. needles… "Where do I sign up". Unfortunately, the MannKind story has been a chal...
Arena Pharmaceuticals, Inc. (ARNA) Q2 2019 Earnings Conference Call August 07, 2019 4:30 PM ET Company Participants Kevin Lind - Chief Financial Officer Amit Munshi - President & Chief Executive Officer Preston Klassen - Head of Research & Development. Conference Call ...
Arena Pharmaceuticals (NASDAQ: ARNA ): Q2 GAAP EPS of -$1.24 misses by $0.17 . Revenue of $1.02M (-74.4% Y/Y) misses by $1.89M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Aug. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2019 . "Arena is off to a strong 2019 and we remain highly focused on achieving several key ...
Listen on the go! Subscribe to The Cannabis Investing Podcast on Libsyn , Spotify , Stitcher or Apple Podcasts . By Jonathan Liss Today I am very happy to welcome Dan Ahrens, manager of the recently launched AdvisorShares Pure Cannabis ETF ( YOLO ) to the ...
AAOI , AGO , AIG , ALB , AMPH , ANGI , ARNA , ASRT , ATO , AVLR , AZPN , BKNG , BREW , CABO , CAI , CCMP , CDE , CECO , CLI , COLL , CPA , CPRX , CSGS , CTL , CVNA , CWH , DAR , DOX , DVAX , EB , ECPG , ENS , ENV , ET , EVRG , FG , FLO , FNV , FOSL , ...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...